CAMBRIDGE, Mass., Nov. 25 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has created a subsidiary company, Fina Technologies, Inc. (Fina) to leverage its proprietary Reverse Engineering, Forward Simulation (REFS(TM)) software platform in a new arena -- that of quantitative financial trading and e-commerce. REFS(TM) was originally developed to rapidly process raw clinical and genomics data to identify drug targets, biomarkers and drug and disease mechanisms for disease categories such as cancer, diabetes and inflammation, and has been used by GNS in partnership with leading pharmaceutical companies and clinical research organizations such as Johnson & Johnson, Pfizer, Novartis AG, Biogen Idec, UCSF Cancer Center, and Jackson Laboratories for these purposes.
"Hidden complex networks govern everything from human diseases to financial markets and the internet, making reliable predictions impossible," said Colin Hill, President and CEO of GNS and Chairman of the Board of Fina: "It is only today that terabytes of data, on-demand supercomputing, and next-generation artificial intelligence software have converged to enable the uncovering of such networks, and prediction of their behavior, such as predicting how a combination of two cancer drugs would affect the size of a tumor in a cancer patient with a particular DNA sequence."
GNS, who developed their proprietary REFS(TM) technology over the past
eight years, uses supercomputers to rapidly accelerate the processing of raw
data into meaningful biomedical outcomes. To date, this REFS(TM) software has
been used to probe and analyze how genes and proteins interconnect in a
complex web with the goal of developing better drugs. Today, GNS has launched
Fina Technolgies (http://www.finatechnologies.com) to monetize their REFS(TM)
technology in the e-commerce and financial trading mark
'/>"/>
| SOURCE Gene Network Sciences, Inc. Copyright©2008 PR Newswire. All rights reserved |